These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 18818704

  • 1. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
    Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB, Jongen-Lavrencic M.
    Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A.
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [Abstract] [Full Text] [Related]

  • 4. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM.
    JAMA; 2011 Jan 05; 305(1):59-67. PubMed ID: 21205967
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.
    Blood; 2009 Apr 16; 113(16):3801-8. PubMed ID: 18941118
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
    Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS.
    Cancer Genet Cytogenet; 2007 Jan 15; 172(2):120-6. PubMed ID: 17213020
    [Abstract] [Full Text] [Related]

  • 10. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S.
    J Clin Oncol; 2010 Oct 10; 28(29):4473-9. PubMed ID: 20697090
    [Abstract] [Full Text] [Related]

  • 11. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De Paoli L, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G.
    Clin Cancer Res; 2009 Feb 01; 15(3):995-1004. PubMed ID: 19188171
    [Abstract] [Full Text] [Related]

  • 12. p53 protein expression in chronic lymphocytic leukemia.
    Sellmann L, Carpinteiro A, Nückel H, Scholtysik R, Siemer D, Klein-Hipass L, Kube D, Dürig J, Dührsen U, Stanelle J, Küppers R.
    Leuk Lymphoma; 2012 Jul 01; 53(7):1282-8. PubMed ID: 22220854
    [Abstract] [Full Text] [Related]

  • 13. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
    Marinelli M, Raponi S, Del Giudice I, De Propris MS, Nanni M, Intoppa S, Milani ML, Mauro FR, Guarini A, Foà R.
    Am J Clin Pathol; 2011 Jan 01; 135(1):173-4. PubMed ID: 21173142
    [No Abstract] [Full Text] [Related]

  • 14. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T, Blonski JZ, Wawrzyniak E, Gora-Tybor J, Palacz A, Dmoszynska A, Konopka L, Warzocha K, Jamroziak K.
    Cancer; 2009 Jan 01; 115(1):94-100. PubMed ID: 19025975
    [Abstract] [Full Text] [Related]

  • 15. [Molecular cytogenetic characteristics of chronic lymphocytic leukemia].
    Xu W, Li JY, Pan JL, Qiu HR, Shen YF, Xiao B, Chen LJ, Wu YF, Sheng RL, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2006 May 01; 28(5):349-52. PubMed ID: 17044998
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.
    Cancer Res; 2006 Dec 15; 66(24):11590-3. PubMed ID: 17178851
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
    Dickinson JD, Joshi A, Iqbal J, Sanger W, Bierman PJ, Joshi SS.
    Int J Mol Med; 2006 May 15; 17(5):769-78. PubMed ID: 16596259
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.